AN2 Therapeutics, Inc. (ANTX) Misses Q4 EPS by 7c

AN2 Therapeutics, Inc. (NASDAQ: ANTX) reported Q4 EPS of ($0.29), $0.07 worse than the analyst estimate of ($0.22).

For earnings history and earnings-related data on AN2 Therapeutics, Inc. (ANTX) click here.

You May Also Be Interested In

• AI and memory not a classic bubble, but future returns uncertain - strategist
• Active options: AMD MSFT GOOGL PLTR MSTR SOFI CRWV NBIS AVGO GME SNDK
• Jefferies on Sarepta Therapeutics (SRPT): 'The risk/reward seems favorable'